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Objectives: To establish biomarkers available as predictors of prognosis and mortality in
heart failure (HF) patients and to correlate the biomarkers with the severity and outcome of
HF.
Methods: This was a prospective study. 60 patients of HF were taken into the study based on
the inclusion and exclusion criteria and were studied for the markers – BNP, TNF-a,
troponin-I, CK-MB, CRP, uric acid, GGT and were compared with the severity and outcome
in these patients.
Results: Of 27 patients with BNP value less than 100 pg/ml, only 1 death occurred (3.7%) and
out of 33 patients with BNP value of more than 100 pg/ml, 8 deaths occurred (24.2%). Out of
the 9 deaths that had occurred, 7 deaths were in the troponin range of >0.5 ng/ml, 2 deaths in
the troponin range of 0.04–0.49 ng/ml, and no deaths in the range of 0–0.03 ng/ml. 8 deaths
had an elevated titer of TNF (40%) and 39 patients out of 40 were survivors who had TNF titers
in the normal range (97.5%).
Conclusion: BNP and TNF-a are excellent predictors of mortality and morbidity in HF.
Troponin-I and CRP have shown signiﬁcance in predicting the outcome in HF. GGT, uric
acid, and CK-MB play no role in predicting the severity and outcome in HF.
# 2015 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier
India, Pvt. Ltd. All rights reserved.
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Heart failure (HF) is a syndrome, rather than a primary
diagnosis, which results from any structural or functional
cardiac disorder that impairs the ability of the heart to support
the physiological circulation.1 Unfortunately, there is no single
diagnostic test for HF, and the accuracy of diagnosis by clinical* Corresponding author.
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0019-4832/# 2015 Cardiological Society of India. Published by Elseviemeans only is often inadequate. Although natriuretic peptides
have been shown to be reliable diagnostic and prognostic tools,
the extent to which these markers could be used as aids in the
titration of medical therapy for chronic heart failure remains
uncertain.1There is an increasing interest in the development of
new biomarkers in evaluation of heart failure, and a great
number of laboratory tests have recently been proposed.2
Studies in which biomarkers are compared are lacking.rthy).
r, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
Table 1 – Baseline characteristics of patients.
Variables Characteristics of patients
Age (years) (mean (SD)) 58.2 (15.73)
Gender
Number (%)
Male 34 (56.7)
Female 26 (43.3)
Diabetes mellitus
Number (%) 14 (23.3)
Hypertension
Number (%) 24 (40)
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data are lacking because of inadequate surveillance systems.3
The epidemiology of HF in India has likely changed from that
reported in 1949 by Vakil.4 The prevalence of HF in India is
possibly on the rise, as India remains doubly burdened by the
rise in the risk factors of traditional cardiovascular disease
(CVD) and by the persistence of pretransitional diseases.3
2. Objectives
To correlate and compare the biomarkers and its values with
the severity outcome of heart failure.
3. Methods
3.1. Source of data
Patients admitted in JSS Hospital, from November 2009 to
November 2011 fulﬁlling the inclusion criteria and exclusion
criteria. Informed consent was taken from all the subjects
enrolled in the study.
3.2. Methodology
Data were collected in a pretested pro forma for 60 in-patients.
Investigations tests such as BNP, CRP, GGT, uric acid, troponin-
I, and CK-MB were done. At the same time, serum samples of
the patients were collected and stored at 20 8C. Patients'
duration of stay, echocardiography ﬁndings, and outcome in
the hospital were followed up.
Later, the serum samples were thawed and brought to room
temperature and ELISA testing of TNF-a was done using ELISA
kits.
3.3. Inclusion criteria
In-patients above 18 years of age and of both sexes admitted to
JSS Hospital fulﬁlling the Framingham criteria for heart failure.
3.4. Exclusion criteria
1. Age less than 18 years.
2. Patients with septic shock, rheumatoid arthritis, ankylosing
spondylosis, Crohn's disease, psoriasis, osteoporosis, co-
lonic cancer, leukemia, tuberculosis, alcoholics, chronic
kidney disease, end stage renal disease patients, and all
other conditions, which can falsely elevate BNP levels were
excluded. Acute coronary syndrome patients were also
excluded from the study.
3.5. Statistical methods
Data were entered in MS-Excel and the statistical methods
were carried out using SPSS for Windows (version 22.0).
Descriptive statistics such as mean, standard deviation (SD),
and percentages were used to describe the variables. In case of
non-normality median and interquartile range (IQR) wereused. Fisher's exact test was used to ﬁnd the association of
biomarkers with mortality, NYHA classiﬁcation, ejection
fraction (EF), and duration of hospital stay. Biomarkers found
signiﬁcant on univariate analysis were identiﬁed as potential
predictors for mortality and duration of hospital stay and were
further evaluated using multivariate logistic regression anal-
yses adjusting for confounding variables. A value of p < 0.05
was considered statistically signiﬁcant.
4. Results
A total of 60 patients with age ranging from 21 years to 95 years
(mean (SD): 58.2 (15.73) years) were included in the study.
Baseline characteristics of the patients were given in Table 1.
There were 34 (56.7%) males and 26 (43.3%) females. There
were 14 (23.3%) diabetic patients and 24 (40%) hypertensive
patients. 11 (18.33%) patients with both diabetic and hyper-
tension. Total number of deaths were 9, maximum being in 41–
60 years age group (44%), whereas least was in the 20–40 years
and 81–95 years age group of 11% each.
The results of univariate analyses for association between
biomarkers and mortality, NYHA classiﬁcation, EF, and
duration of stay showed that all the biomarkers except CKMB
found statistically signiﬁcant association (Table 2). The
median (IQR) value of BNP was 120 pg/ml (54.25–662 pg/ml),
reference range being 0–100 pg/ml. 33 (55%) patients had BNP
>100 pg/ml. 8 (24.2%) deaths occurred in this range which was
statistically signiﬁcant ( p-value = 0.033). In association of BNP
with NYHA grading, it was observed that 14 out of 33 patients
and 11 out of 33 patients who had BNP values of >100 pg/ml,
had NYHA grade of III and IV respectively which was
signiﬁcant when compared with 26 out of 27 patients having
BNP <100 pg/ml had breathlessness of NYHA II which was
found to have highly signiﬁcant association ( p-value <0.001).
Out of 33 patients who had BNP >100 pg/ml, 10 (30.3%) had EF
of <40% whereas 22 out of 27 patients (81.5%) who had BNP
<100 pg/ml had EF >50% which was statistically signiﬁcant ( p-
value = 0.001). Out of 33 patients, 23 (69.7%) had a longer
duration of stay when compared to the lower BNP range in
which 19 out of 27 (70.4%) patients had a shorter duration of
stay which was signiﬁcant ( p-value = 0.002). The median (IQR)
value of troponin-I was 0.15 ng/ml (0.02–0.86 ng/ml), reference
range being >0.50 ng/ml. 22 (36%) patients fall into this
reference range with 7 out of 9 deaths in this range which
Table 2 – Univariate analysis between biomarkers and
mortality.
Mortality (n = 60)
No Yes
BNP
≤100 26 (96.3%) 1 (3.7%) x2 = 4.913, df = 1,
p = 0.033>100 25 (75.8%) 8 (24.2%)
Troponin-I
0–0.03 20 (100.0%) 0 (0%) x2 = 8.240, df = 2,
p = 0.0080.04–0.49 16 (88.9%) 2 (11.1%)
>0.50 15 (68.2%) 7 (31.8%)
CRP
≤0.5 31 (96.9%) 1 (3.1%) x2 = 7.548, df = 1,
p = 0.009>0.5 20 (71.4%) 8 (28.6%)
Uric acid
2–7 47 (92.2%) 4 (7.8%) x2 = 13.659, df = 1,
p = 0.002>7 4 (44.4%) 5 (55.6%)
TNF-a
<0.075 43 (84.3%) 2 (22.2%) x2 = 15.730, df = 1,
p = 0.000>0.075 7 (15.7%) 8 (77.8%)
CK-MB
<20 24 (85.7%) 4 (14.3%) x2 = 0.021, df = 1,
p = 1.000>20 27 (84.4%) 5 (15.6%)
Table 4 – Univariate analysis between biomarkers and
ejection fraction.
Ejection fraction
<40 40–50 >50
BNP
<100 0 (0%) 5 (18.5%) 22 (81.5%) x2 = 13.602, df = 2,
p = 0.001>100 10 (30.3%) 9 (27.3%) 14 (42.4%)
Troponin-I
0–0.03 0 (0%) 1 (5.0%) 19 (95.0%) x2 = 16.321, df = 2,
p = 0.0010.04–0.49 3 (16.6%) 1 (5.6%) 14 (77.8%)
>0.50 7 (31.8%) 12 (54.5%) 3 (13.7%)
CRP
<0.5 0 (0%) 5 (15.6%) 27 (84.4%) x2 = 19.893, df = 2,
p = 0.000>0.5 10 (35.8%) 9 (32.1%) 9 (32.1%)
Uric acid
2–7 9 (17.6%) 10 (19.6%) 32 (62.8%) x2 = 8.489, df = 2,
p = 0.012>7 1 (11.2%) 4 (44.4%) 4 (44.4%)
TNF-a
<0.075 2 (5%) 7 (17.5%) 31 (77.5%) x2 = 28.737, df = 2,
p = 0.009>0.075 8 (40%) 7 (35%) 5 (25%)
CK-MB
<20 5 (55.6%) 3 (37.5%) 20 (46.5%) x2 = 556, df = 2,
p = 0.757>20 4 (44.4%) 5 (62.5%) 23 (53.5%)
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with raised troponin values had NYHA III (50%) and NYHA IV
(40.9%) whereas all patients who had normal troponin group
had NYHA II (100%) which was signiﬁcant ( p = 0.000). Out of 22
patients with raised troponin values, 15 (68.18%) had EF of 40–
60% whereas in the normal troponin group 19 out of 20
patients had EF >60% which was highly signiﬁcant ( p = 0.001).Table 3 – Univariate analysis between biomarkers and
NYHA class.
NYHA class
II III IV
BNP
<100 26 (96.3%) 1 (3.7%) 0 (0%) x2 = 33.766, df = 2,
p = 0.000>100 8 (24.2%) 14 (42.4%) 11 (33.3%)
Troponin-I
0–0.03 20 (100.0%) 0 (0%) 0 (0%) x2 = 39.454, df = 2,
p = 0.0000.04–0.49 12 (66.7%) 4 (22.2%) 2 (11.1%)
>0.50 2 (9.1%) 11 (50.0%) 9 (40.9%)
CRP
<0.5 31 (96.9%) 1 (3.1%) 0 (0%) x2 = 50.119, df = 2,
p = 0.000>0.5 3 (10.7%) 14 (50.0%) 11 (39.3%)
Uric acid
2–7 34 (66.7%) 10 (19.6%) 7 (13.7%) x2 = 15.126, df = 2,
p = 0.000>7 0 (0%) 5 (55.6%) 4 (44.4%)
TNF-a
<0.075 31 (77.5%) 9 (22.5%) 0 (0%) x2 = 32.308, df = 2,
p = 0.000>0.075 3 (15.0%) 6 (30.0%) 11 (55.0%)
CK-MB
<20 15 (44.1%) 8 (53.8%) 5 (45.5%) x2 = 363, df = 2,
p = 0.834>20 19 (55.9%) 7 (46.7%) 6 (54.5%)Out of 22 patients with raised troponin group, 17 (77.3%) had a
longer duration of stay when compared to 14 out of 20 (70%)
patients with normal troponin values had a shorter duration of
stay, p = 0.007. The median (IQR) value of CRP in the study
group was 0.5 mg/dl (0–1.24 mg/dl) which is above the normal
reference range of 0–0.5 mg/dl. 8 out of 9 patients who died had
a raised CRP value with mean value being 4.972 which was
highly signiﬁcant ( p-value <0.001). The patients with CRP of
higher values had 50% NYHA III and 39.3% NYHA IV, whereas
patients in the normal CRP group had 96.9% NYHA II, which isTable 5 – Univariate analysis between biomarkers and
duration of stay in the hospital.
Duration of stay
<6 days >6 days
BNP
<100 19 (70.4%) 8 (29.6%) x2 = 9.547, df = 1,
p = 0.002>100 10 (30.3%) 23 (69.7%)
Troponin-I
0–0.03 14 (70.0%) 6 (30.0%) x2 = 9.914, df = 2,
p = 0.0070.04–0.49 10 (55.6%) 8 (44.4%)
>0.50 5 (22.7%) 17 (77.3%)
CRP
<0.5 20 (62.5%) 12 (37.5%) x2 = 5.511, df = 1,
p = 0.019>0.5 9 (32.1%) 19 (67.9%)
TNF-a
<0.075 24 (60.0%) 16 (40.0%) x2 = 0.834, df = 1,
p = 0.035>0.075 3 (15.0%) 17 (85.0%)
CK-MB
<20 13 (44.8%) 15 (48.4%) x2 = 0.076, df = 1,
p = 0.782>20 16 (55.2%) 16 (51.6%)
Table 6 – Multivariate analysis of mortality as biomarkers as predictors.
Variables b coefﬁcient S.E. Wald p-value OR (95% CI)
Model 1
BNP .154 2.065 .006 .941 1.166 (0.02–66.75)
Gender 1.718 1.468 1.369 .242 .179 (0.01–3.19)
Age .006 .058 .011 .917 .994 (0.89–1.11)
Diabetes .945 1.328 .507 .476 .389 (0.03–5.24)
Hypertension 1.581 1.397 1.280 .258 .206 (0.01–3.18)
Troponin .784 1.375 .325 .569 2.189 (0.15–32.41)
CRP .561 2.276 .061 .805 0.571 (0.007–49.35)
Uric acid 3.527 1.760 4.017 .045 34.015 (1.08–1070.06)
TNF 1.853 1.677 1.222 .269 6.380 (0.24–170.63)
Constant .289 2.900 .010 .921 1.335
Model 2
BNP .011 1.789 .000 .995 1.011 (0.03–33.72)
Troponin .306 1.244 .060 .806 1.358 (0.119–15.55)
CRP 1.529 2.175 .494 .482 0.217 (0.003–15.40)
Uric acid 2.542 1.250 4.139 .042 12.710 (1.09–147.18)
TNF 2.887 1.504 3.684 .055 17.935 (0.94–341.84)
Constant 1.651 1.126 2.152 .142 0.192
Model 1 summary: R2 (Cox and Snell) = 0.370, p-value = 0.002; Model 2 summary: R2 (Cox and Snell) = 0.302, p-value = 0.001. Results of
multivariate analysis of association between mortality and biomarkers those found signiﬁcant in the univariate analysis. Multivariate logistic
regression analysis showed only uric acid (adjusted OR = 34.01, 95% CI = 1.08–1070.05, p-value = 0.045) as the signiﬁcant predictor while taking
age, gender, diabetes, and hypertension as the confounders. Also uric acid remained signiﬁcant predictor after leaving confounders and rerun
the logistic regression (Table 6). The odds of uric acid biomarker with 2–7 will be 12.7 times those of with >7.
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values, 10 (35.8%) had EF <40% whereas in the normal CRP
group 27 out of 32 patients (84.4%) had EF >50%. Out of 28
patients with raised CRP values, 19 (67.9%) had a longer
duration of stay whereas 20 out of 32 patients with normal CRP
values had a shorter duration of stay, p = 0.019. The mean (SD)Table 7 – Biomarkers as predictors for duration of stay in the h
Variables B S.E. 
Model 1
Gender .578 .681 
Age .012 .022 
Diabetes 1.148 .928 
Hypertension .181 .804 
BNP1 1.757 .901 
Troponin 3.217 1.358 
CRP .149 1.183 
Uric acid 2.412 1.128 
TNF 1.782 1.300 
Constant .387 1.488 
Model 2
BNP 1.695 .846 
Troponin 2.932 1.233 
CRP .107 1.082 
Uric acid 2.135 1.052 
TNF 1.499 1.128 
Constant .261 .849 
Model 1 summary: R2 (Cox and Snell) = 0.323, p-value = 0.009; Model 
multivariate analysis of association between duration of stay and bioma
logistic regression analysis showed that troponin and uric were the signi
as the confounders. Also uric acid and troponin remained signiﬁcant pred
regression (Table 7).value of uric acid was 6.02 mg/dl (1.23 mg/dl) which was in the
normal range of 2–7 mg/dl. Out of 9 patients who died, 5
patients had high uric acid which was statistically signiﬁcant
( p = 0.002). Out of 9 patients with raised uric acid levels, 5
(55.6%) had NYHA III and 4 (44.4%) had NYHA IV whereas 34 out
of 51 patients in the normal uric acid range had NYHA II whichospital using multivariate logistic regression.
Wald Sig. OR (95% CI)
.720 .396 0.561 (15–2.13)
.292 .589 0.988 (0.95–1.03)
1.530 .216 3.151 (0.51–19.41)
.050 .822 0.835 (0.17–4.04)
3.800 .051 0.173 (0.03–1.01)
5.614 .018 0.040 (0.003–0.57)
.016 .900 0.862 (0.08–8.76)
4.574 .032 11.157 (1.22–101.76)
1.880 .170 5.942 (0.46–75.90)
.068 .795 1.473
4.016 .045 0.184 (0.035–0.96)
5.655 .017 0.053 (0.005–0.59)
.010 .921 0.898 (0.11–0.83)
4.117 .042 8.453 (1.07–7.49)
1.766 .184 4.478 (0.49–66.45)
.094 .759 0.770
2 summary: R2 (Cox and Snell) = 0.294, p-value = 0.002. Results of
rkers those found signiﬁcant in the univariate analysis. Multivariate
ﬁcant predictors while taking age, gender, diabetes and hypertension
ictors including BNP after leaving confounders and rerun the logistic
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 2 2 – s 2 8S26is signiﬁcant ( p = 0.000). Out of 9 patients who had higher uric
acid levels, 4 patients had EF >50% and 4 patients had EF 40–
50%. Whereas 32 out of 51 patients had EF >50%, who were in
the normal uric acid range. The median (IQR) value of TNF-a
was 0.034 pg/ml (0.012–0.798 pg/ml) which was signiﬁcantly
above the cut-off value of 3 pg/ml. There were 8 out of 9
patients, who died and had a raised TNF value, and the mean
value in the non-survivors was 2091.87 pg/ml, which was
signiﬁcantly higher ( p = 0.000). Of 20 patients with raised TNF
values, 11 patients had NYHA IV and 6 had NYHA III whereas
31 out of 40 (77.5%), who had normal TNF values had NYHA II,
which is signiﬁcant ( p = 0.000). Out of 20 patients with raised
TNF group, 7 (35%) had EF of 40–50% and 8 (40%) had EF <40%
when compared to the normal TNF group in which 31 out of 40
patients had EF >50%. On comparing BNP with TNF, out of 20
patients with raised TNF values, 17 (85%) had BNP >100 pg/ml
which was signiﬁcant, p = 0.001. The median (IQR) value of CK-
MB was 22 U/I (18–27.5 U/I), reference range being >20 U/I.
There was no signiﬁcant association between CK-MB and
mortality.
5. Discussion (Tables 3–5)
In this study, out of the 60 patients studied, there were 9
deaths, i.e., 15% mortality rate was prevalent in our hospital
amongst the heart failure patients.
In this study, a large percentage of patients with heart
failure were due to hypertensive heart disease (37%), second
being dilated cardiomyopathy (25%), third being ischemic
cardiomyopathy (18%), fourth being CKD (13%), and last being
valvular/rheumatic heart disease (7%).
5.1. BNP and mortality and morbidity
The mean BNP value was 444.44 pg/ml in our study, which was
in concordance with most of the studies, which showed BNP
value in the range of 160–1676 pg/ml.
In our study, out of 27 patients with BNP value of less than
100 pg/ml, only 1 death occurred (3.7%) and out of 33 patients
with BNP value of more than 100 pg/ml, 8 deaths occurred
(24.2%), which shows that there is higher death rate with
higher values of BNP ( p = 0.027). The mean value of BNP in non-
survivors was 1486.2 pg/ml, whereas the mean value of BNP in
survivors was 260.6 pg/ml.
In the Italian RED study, out of 247 patients with CHF, 7
deaths occurred with a mean BNP value of 820 pg/ml,6 when
compared to our study, which showed a mean value of
1486.2 pg/ml in the patients whose end-point was death which
is signiﬁcant.
Out of the 33 patients with BNP more than 100 pg/ml, 14
patients (42.4%) had breathlessness of NYHA III and 11
patients (33.3%) had breathlessness of NYHA IV.
Patients with BNP less than 100 pg/ml had predominant
breathlessness of NYHA II of 96.3%. p = 0.000, which is again
signiﬁcant.
In the Italian RED study, out of 247 patients, 33% were in
NYHA III and 67% were in NYHA IV. No candidates of NYHA II
were included in that study and hence the signiﬁcance
reduces, as the comparative ﬁgures are not available.6Also, BNP was signiﬁcantly higher (84.8%) in patients with
EF of less than 60%, of which 24.2% had EF <40% and 60.6% had
EF 40–60%, which was in concordance with the study done by
Dao et al., which showed 51% higher rate of BNP in LVEF of less
than 55%.7
Another signiﬁcant ﬁnding was that in the group of BNP
more than 100 pg/ml, 23 patients had a in-hospital stay of
more than 6 days (69.7%) in comparison to the group of BNP
value of less than 100 pg/ml, where the in-hospital stay was
less than 6 days, p = 0.002.
Thus, in our study there has been a signiﬁcant relation
between the in-hospital stay, mortality, NYHA grading, EF on
echocardiography, and BNP.
5.2. Troponin-I and mortality and morbidity
Out of the 9 deaths that had occurred, 7 deaths were in the
troponin range of >0.5 ng/ml, 2 deaths in the troponin range of
0.04–0.49 ng/ml, and no deaths in the range of 0–0.03 ng/ml,
with signiﬁcance of p = 0.013. The mean value of troponin-I in
the patients, who dies was 2.03 ng/ml, whereas the mean
value of troponin-I in survivors was 0.61 ng/ml. Peacock et al.
have stated in a study that troponin-raised patients had a
higher rate of in-hospital mortality than troponin-negative
patients (8.0% vs. 2.7%, p < 0.001).8
In our study, out of the 60 patients 20 patients had negative
troponin values and all of them were in NYHA class II, and out
of the remaining 40 patients, 22 patients had troponin range
>0.5 ng/ml, out of which 11 were in NYHA class III and 9 were
in NYHA class IV with signiﬁcance of p = 0.000.
Whereas, a study done by Horwich et al. did not show
signiﬁcance of troponin-I in NYHA grading, with 41% with
<0.04 ng/ml of troponin and 59% with >0.04 ng/ml with
p = 0.056.9
In a study by Biolo et al., the mean EF in acute heart failure
patients was 24%.10
In our study only 20% of patients with raised troponin
values had past history of an acute coronary event. Hence
the possibility of a bias due to the acute coronary event is
lesser.
In our study, the positivity (90.9%) of troponin was very high
in patients with EF <50% of which, 31.8% had EF <40% and in
the negative troponin value group, 20 patients (75%) had EF
>50%. This clearly shows the importance of troponin-I in heart
failure as the p value = 0.000. Hence it is a prognostic marker
and not a diagnostic marker.
5.3. CK-MB and mortality
When correlated with death, EF, duration of stay, and NYHA
class, there was no signiﬁcance in the values of CK-MB.
5.4. C-reactive protein
The mean CRP value of the patients, who died was 4.97 mg/dl,
which was signiﬁcantly above the normal range. CRP was also
strongly related to the NYHA class. With raised CRP values, the
patients were likely to be in NYHA class III and IV when
compared to the negative CRP group. In a study by Alonso-
Martínez et al., the mean CRP value was 9.35 mg/dl which is
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 2 2 – s 2 8 S27higher than in our study.11 A study by Suleiman et al., also
showed that CRP levels increased with the grading of
breathlessness with p = 0.001.12
5.5. Gamma glutamyl transferase
In our study the mean value of GGT was 34 U/l, which was not
signiﬁcant.
Also, on cross tabulation there was no signiﬁcance in GGT
titers and mortality, NYHA, and EF. Whereas, in a study by
Dhingra et al., cumulative incidence curves demonstrated a
greater risk of new-onset heart failure among individuals with
a serum GGT concentration at or greater than the median
compared with those with levels less than the median
( p < 0.001, log-rank test), which is not corresponding to our
study.13
5.6. Uric acid
In our study, the mean value of uric acid was 6.023 mg/dl,
which is in the normal range of 2–7 mg/dl. In a study by Anker
et al., the best cut-off value for predicting mortality was
9.5 mg/dl, which is much higher, when compared to our
study.14 No signiﬁcant univariate correlation emerged be-
tween serum uric acid and left ventricular EF.
5.7. Tumor necrosis factor-a
The mean value of TNF-a in our study was 550 pg/ml. This was
a signiﬁcantly high titer. 55% of the patients with raised TNF
titers were in NYHA class IV when compared to 77.5% of
patients with negative titers who were in NYHA class II,
p = 0.000. Also, our study showed higher percentage (85%) of
patients with raised titers of TNF with EF <60%, of which 50%
of the patients had EF of 40–60% and 35% of them had EF <40%,
p = 0.009. In a study by Bradham et al., the LVEF mean value
was around 22% in patients with raised TNF titers and heart
failure.15
However, there was no signiﬁcant correlation between TNF
titers and the duration of in-hospital stay in our study,
p = 0.361. In a study by Dunlay et al., the death rate was 30.2%
in comparison to TNF, which was in concordance to our study.
No association was found between TNF-a and NYHA func-
tional class in the study by Dunlay et al.16
6. Conclusion
The main conclusions from this study are:
- BNP is an established and an excellent predictor of mortality
and morbidity in heart failure.
- TNF-a has also been a very good predictor of mortality and
morbidity with signiﬁcant correlation with BNP.
- Troponin-I and CRP have also shown signiﬁcance in
predicting the outcome in heart failure but not as much as
BNP and TNF-a.
- GGT, uric acid, and CK-MB play no role in predicting the
severity and outcome in heart failure in our study.Though BNP has already been established as a biomarker for
measuring the progress of a patient after regular treatment,
the other biomarkers such as troponin-I and CRP, which have
been studied here, which are of lower cost can also be used to
quantify the response of the treatment given in patients with
heart failure.
6.1. Limitations of this study
This was a single center study with a small sample size; but
this can be a pilot study for future large-scale multicentric
studies.
6.2. Strengths of this study
Many cardiac biomarkers were compared with the outcome in
this study. There are no previous studies from this part of the
country; multicentric studies might bring out any genetic
factors, which might affect the outcome.
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